Omalizumab in allergic bronchopulmonary aspergillosis in patients with cystic fibrosis

Figures & data

Table 1 Clinical outcomes

Patient	FEV1 pre %pred	FEV1 post %pred	BMI pre Z score	BMI post Z score	IgE post kU/L	IgE post kU/L	PEx Number	Steroids pre	Steroids post
1	69	54	−1.3	−1.35	1,570	387	2	Pulse	Pulse
2	83	71	−1	−0.69	7,560	5,240	4	C
3	61	62	−1.45	−1.45	3,280	3,900	0	C
4	80	79	0.57	0.78	12,000	14,200	0	C
5	76	54	−3.4	−4.1	1,180	299	4	C
6	72	74	−1.7	−2.7	472	274	3	0.1 mg/kg	0.1 mg/kg
7	39	29	−2.6	−3.1	667	172	17	0.25 mg/kg	0.25 mg/kg
8	36	33	−0.3	−1.1	715	488	6	C
9	25	30	−4.7	−4	2,690	5,000	0	0.63 mg/kg	0.63 mg/kg

Abbreviations: BMI, body mass index; C, contra-indication; FEV₁, forced expiratory volume in 1 second; PEx, pulmonary exacerbation.

Table 2 Patient data

Patient	Age (years)	Gender	Mutations	CFRD	Tx duration (months)	Dose of omalizumab	Center
1	32	M	W1282X/F508del	Yes	26	375 mg	RMC IL
2	19	M	W1282X/W1282X	Yes	8	375 mg	SMC IL
3	27	F	W1282X/G542X	Yes	15	375 mg	SMC IL
4	16	M	W1282X/D1152H	No	5	375 mg	SMC IL
5	12	M	N1303K/N1303K	Yes	12	375 mg	SMC IL
6	24	M	F508del/F508del	No	12	375 mg	Leuven BE
7	21	M	F508del/F508del	Yes	18	300 mg	Leuven BE
8	41	F	F508del/F508del	Yes	27	375 mg	Leuven BE
9	15	F	F508del/R553X	Yes	2	375 mg	Leuven BE

Abbreviations: CFRD, cystic fibrosis-related diabetes; M, male; F, female; SMC, Sheba Medical Center; RMC, Rambam Medical Center; BE, Belgium.

Figure 1 FEV₁ before and after treatment with omalizumab.

Note: Colored lines represents individual patients.
Abbreviation: FEV₁, forced expiratory volume in 1 second.

Figure 2 BMI before and after treatment with omalizumab.

Note: Colored lines represents individual patients.
Abbreviation: BMI, body mass index.

Figure 3 Comparison between patients whose IgE level increased during treatment and patients whose level declined.

Abbreviations: FEV₁, forced expiratory volume in 1 second.